Our Mission

The mission of PPMI is to identify one or more biomarkers of Parkinson’s disease progression. The discovery of a biomarker is a critical step in the development of new and better treatments for PD. This study is being sponsored by The Michael J. Fox Foundation for Parkinson's Research.



PPMI Enrollment Status

68%
Genetic Cohort Participants
Enrollment Goal: 600

72%
Genetic Registry Participants
Enrollment Goal: ~600

100%
De Novo PD Participants
Enrollment: 423

100%
Control Participants
Enrollment: 196

100%
Subjects with SWEDD
Enrollment: 64

100%
Prodromal Participants
Enrollment: 65

Last Update: May 22 2017

 

More about study cohorts >

A Landmark Study of Parkinson’s Disease

The Parkinson’s Progression Markers Initiative (PPMI) is a landmark observational clinical study to comprehensively evaluate cohorts of significant interest using advanced imaging, biologic sampling and clinical and behavioral assessments to identify biomarkers of Parkinson’s disease progression.

PPMI is taking place at clinical sites in the United States, Europe, Israel, and Australia. Data and samples acquired from study participants will enable the development of a comprehensive Parkinson’s database and biorepository, which is currently available to the scientific community to conduct field-changing research.

PPMI is made possible by the concerted efforts of a number of collaborators. This study is sponsored by The Michael J. Fox Foundation for Parkinson’s Research.

Learn more about Who We Are.

LATEST NEWS FROM PPMI

PPMI iPSC Lines — A Valuable Tool for Researchers

The Parkinson’s Progression Markers Initiative (PPMI) has expanded to include the generation of induced pluripotent stem cell (iPSC) lines from reprogrammed peripheral mononuclear blood cells (PBMCs) collected from PPMI participants. Study leadership hopes to complete 135 blood collections by the end of 2017; to date, over 50 PPMI participants have given blood samples. Cells lines […]


Live Webinar February 24: 2016 PPMI Data Challenge Winners

In June of 2016, The Michael J. Fox Foundation challenged data scientists and computational analysts to work with PPMI’s unprecedented collection of open-access clinical, molecular, and imaging data to answer two fundamental questions about Parkinson’s disease: what are the subtypes of the disease, and what baseline factors predict disease progression? In total, forty researchers submitted […]


The Michael J. Fox Foundation Announces $25,000 PPMI Data Challenge to Advance Parkinson’s Understanding and Study Design

Today The Michael J. Fox Foundation (MJFF) announced a challenge asking data scientists and computational analysts to work with researchers to answer fundamental questions about Parkinson’s that limit our understanding and slow drug testing. The PPMI Data Challenge offers $25,000 each to two teams that develop models to answer either: • What factors at baseline predict […]


2016 PPMI Annual Meeting held in New York City

The 2016 PPMI annual meeting took place on May 4-5 in New York City.  The meeting brought together 175 PPMI stakeholders from around the world, including PPMI leadership, site principal investigators, site coordinators and industry partners.  During the two day meeting, there was discussion of the data coming out of PPMI to date, plans for the […]


PPMI Q1 2016 Study Update call

On March 11, Dr. Mark Frasier, Senior Vice President at the Michael J. Fox Foundation, shared an update on the PPMI study. Dr. Frasier summarized some of the key accomplishments of PPMI to date.


Learn More